Moreover, in preclinical RMS models, tumor-derived G-CSF was identified as one of the key factors driving the expansion of MDSCs, thereby limiting the efficacy of chimeric antigen receptor (CAR) T-cell therapy [59]. This evidence concerns the gene CSF3 and neoplasm.